Our ambition is to navigate and help our clients through the “waters” of pre- and post-approval market access challenges.

GIPAM is a global health research consultancy specialized in strategic market access and real-world evidence.

With our team of dedicated, experienced, and highly skilled consultants and our network of data providers, clinicians, and HTA experts/payors, we deliver what we promise. We strongly believe in high scientific standards and full transparency in all of our studies and projects – that is our GIPAM way.

The three majority owners of GIPAM - Jason Simeone, Sabrina Müller, and Thomas Wilke - have more than 40 years of experience in strategic market access and Real-World Evidence (RWE) studies.

Maria Rizzo

Head of Evidence Synthesis & Partner

With over 18 years of experience, Maria Rizzo began her career producing systematic literature reviews and meta-analyses for the National Institute for Health and Care Excellence (NICE).
She has since held global HEOR roles at Evidera and Cencora, supporting evidence generation for HTA submissions. Most recently, as Vice President of Evidence Review and Software at Cytel, she expanded the development and commercialization of LiveSLR®, a literature review platform to support HTA submissions.
Maria is now leading the Evidence Synthesis, Modeling and Access capabilities at GIPAM. As part of this role, she is also overseeing the development of GIPAM’s ANCHOR, an evidence synthesis platform.

Jason Simeone

Managing Director & Partner

Dr. Jason Simeone is the Head of GIPAM US.
With over 15 years of experience as a pharmacoepidemiologist, Jason has extensive expertise in conducting real-world evidence (RWE) studies across the United States, EU, and other markets.
Jason is leading our US activities, offering full-service RWE support, including drug safety, comparative effectiveness, burden of illness, database feasibility, landscaping studies, and evidence synthesis.

Sabrina Müller

Managing Director & Partner

Sabrina Müller is the Managing Director of GIPAM EU.
She has more than ten years of experience in conducting and leading health economic and real-world evidence projects and worked previously for companies such as IPAM, Ingress-Health, and Cytel.
Sabrina is specialized in advanced trial & database analyses as well as in adherence/persistence & preference studies.

Thomas Wilke

Scientific Lead & Partner

Prof. Dr. Thomas Wilke is the Scientific Leader of GIPAM.
He has 20 years of experience in leading and conducting real-world evidence studies.
Thomas leads the IPAM research institute, founded Ingress-Health, and worked for 3.5 years as Global RWE Lead for Cytel.
He brings a wealth of experience with respect to a broad range of different RWE research activities and is a specialist in strategic evidence generation planning.